JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1992; 19:1315-1321
© 1992 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ballantyne, C.
Right arrow Articles by Gotto, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ballantyne, C.
Right arrow Articles by Gotto, A., Jr

Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations

CM Ballantyne, B Radovancevic, JA Farmer, OH Frazier, L Chandler, C Payton-Ross, B Cocanougher, PH Jones, JB Young, and AM Gotto Jr

Department of Medicine, Methodist Hospital, Houston, Texas.

Mean plasma lipid values in 100 patients who survived greater than 3 months after heart transplantation increased significantly at 3 months over pretransplantation values: total cholesterol from 168 +/- 7 to 234 +/- 7 mg/dl, low density lipoprotein (LDL) cholesterol from 111 +/- 6 to 148 +/- 6 mg/dl, high density lipoprotein (HDL) cholesterol from 34 +/- 1 to 47 +/- 1 mg/dl and triglycerides from 107 +/- 6 to 195 +/- 10 mg/dl. There were no significant increases after this time. The LDL cholesterol values reamined greater than or equal to 130 mg/dl in 64% of patients and triglyceride values remained greater than or equal to 200 mg/dl in 41% of patients 6 months after postoperative dietary instructions. Beginning in 1985, select patients whose total cholesterol values remained greater than 300 mg/dl despite 6 months of dietary intervention were treated with lovastatin given alone in a high dose (40 to 80 mg/day) or in combination with another hypolipidemic agent. Four of the five patients so treated developed rhabdomyolysis; two of the four had acute renal failure. Beginning in 1988, a second protocol--lovastatin at 20 mg/day as monotherapy--was used in patients who despite dietary intervention had total cholesterol greater than 240 mg/dl (mean follow-up 13 months). In the 15 patients so treated, mean total cholesterol decreased from 299 +/- 10 mg/dl before treatment with lovastatin to 235 +/- 9 mg/dl during treatment (21% reduction, p less than 0.001) and mean LDL cholesterol was reduced from a baseline value of 190 +/- 10 to 132 +/- 12 mg/dl during treatment (31% reduction, p less than 0.001). In this study, lovastatin at a dose of less than or equal to 20 mg/day as monotherapy was a well tolerated, effective treatment for hyperlipidemia after heart transplantation. It did not result in rhabdomyolysis and required no alteration in immunosuppressive therapy. However, the dose should not exceed 20 mg/day and combination therapy with either gemfibrozil or nicotinic acid should be avoided, even if the target LDL cholesterol value is not reached.


This article has been cited by other articles:


Home page
J CARDIOVASC PHARMACOL THERHome page
N. Z. Sulemanjee, R. Merla, S. D. Lick, S. M. Aunon, M. Taylor, M. Manson, L. S.C. Czer, and E. R. Schwarz
The First Year Post-Heart Transplantation: Use of Immunosuppressive Drugs and Early Complications
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2008; 13(1): 13 - 31.
[Abstract] [PDF]


Home page
CirculationHome page
J. Lindenfeld, R. L. Page II, R. Zolty, S. F. Shakar, M. Levi, B. Lowes, E. E. Wolfel, and G. G. Miller
Drug Therapy in the Heart Transplant Recipient: Part III: Common Medical Problems
Circulation, January 4, 2005; 111(1): 113 - 117.
[Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
S. de Denus, A. Al-Jazairi, E. Loh, M. Jessup, E. J Stanek, and S. A Spinler
Dyslipidemias and HMG-CoA Reductase Inhibitor Prescription in Heart Transplant Recipients
Ann. Pharmacother., July 1, 2004; 38(7): 1136 - 1141.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
C. M. Ballantyne, A. Corsini, M. H. Davidson, H. Holdaas, T. A. Jacobson, E. Leitersdorf, W. Marz, J. P. D. Reckless, and E. A. Stein
Risk for Myopathy With Statin Therapy in High-Risk Patients
Arch Intern Med, March 10, 2003; 163(5): 553 - 564.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. C. Fang, S. Kinlay, D. Behrendt, H. Hikita, J. L. Witztum, A. P. Selwyn, and P. Ganz
Circulating Autoantibodies to Oxidized LDL Correlate With Impaired Coronary Endothelial Function After Cardiac Transplantation
Arterioscler. Thromb. Vasc. Biol., December 1, 2002; 22(12): 2044 - 2048.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
J.-W. Park, R. Siekmeier, P. Lattke, M. Merz, C. Mix, S. Schuiler, and W. Jaross
Pharmacokinetics and Pharmacodynamics of Fluvastatin in Heart Transplant Recipients Taking Cyclosporine A
Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2001; 6(4): 351 - 361.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
M. Weis, S. Pehlivanli, B. M. Meiser, and W. von Scheidt
Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation
J. Am. Coll. Cardiol., September 1, 2001; 38(3): 814 - 818.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
F. D. Knollmann, M. Hummel, R. Hetzer, and R. Felix
CT of Heart Transplant Recipients: Spectrum of Disease
RadioGraphics, November 1, 2000; 20(6): 1637 - 1648.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
M. Bottorff and P. Hansten
Long-term Safety of Hepatic Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitors: The Role of Metabolism--Monograph for Physicians
Arch Intern Med, August 14, 2000; 160(15): 2273 - 2280.
[Full Text] [PDF]


Home page
CirculationHome page
D. H. Walter, J. Haendeler, J. Galle, A. M. Zeiher, and S. Dimmeler
Cyclosporin A Inhibits Apoptosis of Human Endothelial Cells by Preventing Release of Cytochrome C From Mitochondria
Circulation, September 22, 1998; 98(12): 1153 - 1157.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1992 by the American College of Cardiology Foundation.